
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Document Content</title>
    <style>
        body { font-family: Arial, sans-serif; line-height: 1.6; max-width: 900px; margin: auto; padding: 20px; }
        table { border-collapse: collapse; width: 100%; margin-top: 20px; margin-bottom: 20px; }
        th, td { border: 1px solid #cccccc; text-align: left; padding: 8px; font-size: 12px; }
        tr:nth-child(even) { background-color: #f9f9f9; }
        th { background-color: #3366CC; color: white; font-weight: bold; }
        h2 { color: #4F81BD; border-bottom: 2px solid #4F81BD; padding-bottom: 5px;}
        p { margin-block-start: 0.5em; margin-block-end: 0.5em; }
    </style>
</head>
<body>
    <p style="font-size: small; color: grey;"><i>Page 96 of 114</i></p>
<p style="font-size: small; color: grey;"><i>Document</i></p>
<p style="font-size: small; color: grey;"><i>Aerie_10k_096.pdf</i></p>
<p>AERIE PHARMACEUTICALS, INC. Consolidated Statements of Cash Flows (in thousands)</p>

<table>
	<tr>
		<th rowspan="2"></th>
		<th colspan="3">YEAR ENDED DECEMBER 31,</th>
	</tr>
	<tr>
		<th>2017</th>
		<th>2016</th>
		<th>2015</th>
	</tr>
	<tr>
		<td>Cash flows from operating activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Net loss</td>
		<td>$ (145,105)</td>
		<td>$ (99,059)</td>
		<td>$ (74,363)</td>
	</tr>
	<tr>
		<td>Adjustments to reconcile net loss to net cash used in operating activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Depreciation</td>
		<td>1,410</td>
		<td>970</td>
		<td>252</td>
	</tr>
	<tr>
		<td>Amortization of debt discounts</td>
		<td>306</td>
		<td>303</td>
		<td>305</td>
	</tr>
	<tr>
		<td>Amortization and accretion of premium or discount on investments, net</td>
		<td>9</td>
		<td>525</td>
		<td>570</td>
	</tr>
	<tr>
		<td>Acquisition of assets expensed to research and development</td>
		<td>24,802</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Stock-based compensation</td>
		<td>26,078</td>
		<td>16,794</td>
		<td>12,945</td>
	</tr>
	<tr>
		<td>Unrealized foreign exchange loss</td>
		<td>601</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Changes in operating assets and liabilities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Prepaid, current and other assets</td>
		<td>(2,239)</td>
		<td>(1,852)</td>
		<td>(840)</td>
	</tr>
	<tr>
		<td>Accounts payable, accrued expenses and other current liabilities</td>
		<td>925</td>
		<td>2,479</td>
		<td>5,385</td>
	</tr>
	<tr>
		<td>Net cash used in operating activities</td>
		<td>(93,213)</td>
		<td>(79,840)</td>
		<td>(55,746)</td>
	</tr>
	<tr>
		<td>Cash flows from investing activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Acquisition of assets from Envisia</td>
		<td>(10,500)</td>
		<td>—</td>
		<td>—</td>
	</tr>
	<tr>
		<td>Purchase of available-for-sale investments</td>
		<td>(104,490)</td>
		<td>(35,169)</td>
		<td>(46,872)</td>
	</tr>
	<tr>
		<td>Proceeds from sales and maturities of investments</td>
		<td>88,153</td>
		<td>58,346</td>
		<td>59,534</td>
	</tr>
	<tr>
		<td>Purchase of property, plant and equipment</td>
		<td>(15,970)</td>
		<td>(5,077)</td>
		<td>(3,280)</td>
	</tr>
	<tr>
		<td>Net cash (used in) provided by investing activities</td>
		<td>(42,807)</td>
		<td>18,100</td>
		<td>9,382</td>
	</tr>
	<tr>
		<td>Cash flows from financing activities</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Proceeds from sale of common stock, net</td>
		<td>134,215</td>
		<td>167,383</td>
		<td>50,451</td>
	</tr>
	<tr>
		<td>Proceeds related to issuance of stock for stock-based compensation arrangements, net</td>
		<td>1,429</td>
		<td>1,242</td>
		<td>1,387</td>
	</tr>
	<tr>
		<td>Net cash provided by financing activities</td>
		<td>135,644</td>
		<td>168,625</td>
		<td>51,838</td>
	</tr>
	<tr>
		<td>Net change in cash and cash equivalents</td>
		<td>(376)</td>
		<td>106,885</td>
		<td>5,474</td>
	</tr>
	<tr>
		<td>Cash and cash equivalents, at beginning of period</td>
		<td>197,945</td>
		<td>91,060</td>
		<td>85,586</td>
	</tr>
	<tr>
		<td>Cash and cash equivalents, at end of period</td>
		<td>$ 197,569</td>
		<td>$ 197,945</td>
		<td>$ 91,060</td>
	</tr>
	<tr>
		<td>Supplemental disclosures</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Cash paid for interest</td>
		<td>$ 2,188</td>
		<td>$ 2,192</td>
		<td>$ 2,186</td>
	</tr>
	<tr>
		<td>Cash paid for income taxes</td>
		<td>$ —
</td>
		<td>$ 1,790</td>
		<td>$ 600</td>
	</tr>
	<tr>
		<td>Non-cash investing and financing activities:</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
	<tr>
		<td>Equity issued for Envisia Asset Acquisition</td>
		<td>$ 14,302</td>
		<td>$ —
</td>
		<td>$ —
</td>
	</tr>
	<tr>
		<td>Capital lease obligation</td>
		<td>$ 689</td>
		<td>$ —
</td>
		<td>$ —
</td>
	</tr>
	<tr>
		<td>Deferred costs from the sale of common stock</td>
		<td>$ 403</td>
		<td>$ 70
</td>
		<td>$ —

</td>
	</tr>
	<tr>
		<td>Build-to-suit lease transaction (Note 5)</td>
		<td></td>
		<td></td>
		<td></td>
	</tr>
</table>
<p>The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="font-size: small; color: grey;"><i>file://usmdcvdi003.us.kworld.kpmg.com/GDC_Ops/Operations/Gayathri%20Krishnan/RPA%20Phase%20II/Kiran/HealthCare/ ... 7/23/2018</i></p>
<p style="font-size: small; color: grey;"><i>F-7</i></p>

</body>
</html>
